PCSK9 Inhibitors: California
March 1, 2018
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in California from January 2017 through December 2017.
Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had the highest rates of rejections:
• BS of CA – 60%
• Express Scripts – 48%
• Centene – 46%
• Anthem – 40%
The following had the lowest rates of rejection:
• Aetna – 14%
• Humana Health Plan – 9%
Categorized in: Report Cards